Morbimortalidad en el lupus eritematoso sistémico
Palabras clave:
Morbimortalidad, lupus eritematoso sistémico, enfermedad autoinmune crónica
Resumen
El Lupus Eritematoso Sistémico (LES) es una enfermedad autoinmune crónica que muestra una amplia diversidad en su expresión clínica y que puede manifestarse de una forma leve hasta formas que comprometen la vida del paciente dependiendo de los órganos afectados y de los fenómenos inmunológicos presentes. La enfermedad se caracteriza por alternar períodos de actividad y de remisión o baja actividad.Citas
I. Drenkard C, Villa AR, García Padilla C, et al. Remission of systemic lupus erythematosus. Medicine (Baltimore) 1996; 75(2):88-98.
II. Leblanc BA, Urowitz MB, Gladman OD. Serologically active, clinically quiescent systemic lupus erythematosus long term follow up. J Rheumatol 1994; 21(1):174-5.
III. Bernatsky S, Boivin JF, Joseph L, et al. Mortality in systemic lupus erythematosus. Arthritis Rheum 2006; 54(8):2550-7.
IV. Uramoto KM, Michet CJ Jr, Thumboo J, et al. Trends in incidence and mortality of systemic lupus erythematosus, 1950-1992. Arthritis Rheum 1999; 42(1):46-50.
V. Cervera R, Khamashta MA, Font J, et al. Morbidity and mortality in systemic lupus erythematosus during 5 year period. A multicenter prospective study of 1000 patients European Working party on Systemic Lupus Erythematosus. Medicine (Baltimore) 1999; 78(3):67-75.
VI. Drenkard C, Alarcon Segovia D. The new prognosis of systemic lupus erythematosus: treatment free remission and decreased mortality
and morbidity. Isr Med Assoc J 2000; 2 (5):382-7.
VII. Urowitz MB, Bookman AA, Koehler BE, et al. The bimodal mortality pattern of systemic lupus erythematosus. Am J Med 1976; 60 (2):221-5.
VIII. Cannon CP. The IDEAL cholesterol: lower is better. JAMA 2005; 294:2492-5.
IX. Nived O, Jonsen A Bengtsson A, et al. High predictive value of SLICC for survival in Systemic lupus erythematosus. J Rheumatol 2002; 29:1398-400.
X. Van Vollenhoven RF, Mosca M, Bertsias G, et al. Treat to target in systemic lupus erythematosus: of an international Task Force. Ann Rheum Dis 2014; 00:1-10.
II. Leblanc BA, Urowitz MB, Gladman OD. Serologically active, clinically quiescent systemic lupus erythematosus long term follow up. J Rheumatol 1994; 21(1):174-5.
III. Bernatsky S, Boivin JF, Joseph L, et al. Mortality in systemic lupus erythematosus. Arthritis Rheum 2006; 54(8):2550-7.
IV. Uramoto KM, Michet CJ Jr, Thumboo J, et al. Trends in incidence and mortality of systemic lupus erythematosus, 1950-1992. Arthritis Rheum 1999; 42(1):46-50.
V. Cervera R, Khamashta MA, Font J, et al. Morbidity and mortality in systemic lupus erythematosus during 5 year period. A multicenter prospective study of 1000 patients European Working party on Systemic Lupus Erythematosus. Medicine (Baltimore) 1999; 78(3):67-75.
VI. Drenkard C, Alarcon Segovia D. The new prognosis of systemic lupus erythematosus: treatment free remission and decreased mortality
and morbidity. Isr Med Assoc J 2000; 2 (5):382-7.
VII. Urowitz MB, Bookman AA, Koehler BE, et al. The bimodal mortality pattern of systemic lupus erythematosus. Am J Med 1976; 60 (2):221-5.
VIII. Cannon CP. The IDEAL cholesterol: lower is better. JAMA 2005; 294:2492-5.
IX. Nived O, Jonsen A Bengtsson A, et al. High predictive value of SLICC for survival in Systemic lupus erythematosus. J Rheumatol 2002; 29:1398-400.
X. Van Vollenhoven RF, Mosca M, Bertsias G, et al. Treat to target in systemic lupus erythematosus: of an international Task Force. Ann Rheum Dis 2014; 00:1-10.
Publicado
2015-03-01
Cómo citar
1.
Alba P. Morbimortalidad en el lupus eritematoso sistémico. Rev. Argent. Reumatol. [Internet]. 1 de marzo de 2015 [citado 24 de abril de 2024];26(1):7 -8. Disponible en: https://ojs.reumatologia.org.ar/index.php/revistaSAR/article/view/623
Sección
Editorial
Derechos de autor 2015 A nombre de los autores. Derechos de reproducción: Sociedad Argentina de Reumatología
Esta obra está bajo licencia internacional Creative Commons Reconocimiento-NoComercial-SinObrasDerivadas 4.0.
